使用快速可吸收明胶微球行膝动脉栓塞治疗骨关节炎相关膝痛
这项前瞻性单中心观察性研究纳入2024年7月至11月194例保守治疗无效的骨关节炎相关膝痛患者,共行239次使用快速可吸收明胶微球(RRGM)的膝动脉栓塞(GAE)。术后6周、3、6、12个月评估安全性及NRS、KOOS。结果显示技术成功率100%,12个月时NRS由7降至3(P<.001),55%-80%受试者KOOS各子评分改善超过MCID,无中重度不良事件。
要点
- 对保守治疗无效的OA膝痛,GAE使用RRGMs在12个月将中位NRS由7降至3(P<.001)。
- 239次操作技术成功,无中重度不良事件,一过性皮肤变色发生率为6.3%。
- 12个月时55%-80%受试者KOOS各子评分改善超过MCID,随访应记录NRS与KOOS。
核心结论
- 膝动脉栓塞使用快速可吸收明胶微球治疗骨关节炎相关膝痛安全,并在12个月带来临床有意义的改善。
研究设计与样本
- 前瞻性、单中心观察性研究,纳入2024年7月至11月连续194例保守治疗无效的骨关节炎相关膝痛患者,共行239次GAE。
- 术后6周、3、6、12个月评估安全性、NRS(0-10分)和KOOS(0-100分),采用描述性统计和Friedman非参数重复测量检验。
诊断标准与关键数值
- 239次操作技术成功率为100%(239/239)。
- 中位NRS由基线7(IQR,6-8)降至12个月3(IQR,2-5)(P<.001),中位降低4分(95%CI:3.5,4.0)。
- 12个月时55%-80%受试者在KOOS所有子评分中改善超过最小临床重要差异。
- 一过性皮肤变色发生于15次术后(6.3%),1例腹股沟浅表血肿(0.4%),均无后遗症。
- 无中重度不良事件;12个月随访率为79%(154/194)。
临床应用与阅片要点
- 对保守治疗无效的OA相关膝痛患者,可考虑使用RRGMs行GAE,12个月时疼痛评分显著下降。
- 术后需观察一过性皮肤变色和腹股沟浅表血肿,本研究中均无后遗症。
- 随访应量化NRS与KOOS,以改善超过MCID作为临床获益判断参考。
局限性
- 单中心观察性设计,样本代表性有限,结果外推需谨慎。
- 12个月随访率为79%(154/194),远期结果解读需考虑失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Genicular artery embolization (GAE) is an emerging minimally invasive therapy for osteoarthritis (OA)-related knee pain. Traditional embolic agents such as imipenem-cilastatin and permanent microspheres have distinct limitations. Rapidly resorbable gelatin-based microspheres (RRGMs), designed specifically for GAE, may offer a promising alternative. Purpose To evaluate the safety and clinical outcomes of GAE using RRGMs in participants with OA-related knee pain. Materials and Methods This prospective, single-center observational study included consecutive participants with OA-related knee pain refractory to conservative treatment who underwent GAE using RRGMs between July and November 2024. Safety, the numeric rating scale (NRS) score (range, 0-10), and the Knee Injury and Osteoarthritis Outcome Score (KOOS) (range, 0-100) were assessed at 6 weeks and 3, 6, and 12 months after treatment. Clinical benefits were evaluated using the minimum clinically important difference (MCID). Descriptive statistics were used, and changes over time were assessed with the Friedman nonparametric repeated-measures test. Results A total of 194 participants (median age, 69 years; IQR, 60.5-75 years; 114 female) underwent 239 GAE procedures using RRGMs. The follow-up rates were 94% at 6 weeks (183 of 194 participants), 89% at 3 months (172 of 194 participants), 89% at 6 months (171 of 194 participants), and 79% at 12 months (154 of 194 participants). All the procedures (239 of 239) were technically successful. Transient skin discoloration occurred after 15 procedures (6.3%), and one participant developed a superficial groin hematoma (0.4%), all of which resolved without sequelae. No moderate or severe adverse events were observed. The median NRS pain score decreased from 7 (IQR, 6-8) at baseline to 3 (IQR, 2-5) at 12 months (P < .001), corresponding to a median reduction of 4 points (95% CI: 3.5, 4.0). At 12 months, 55%-80% of participants achieved improvements exceeding the MCID across all KOOS subscores. Conclusion GAE using RRGMs is safe and is associated with clinically meaningful improvement in participants with OA-related knee pain. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.
引用
- Fleckenstein, David, Garducci, et al. Genicular Artery Embolization Using Rapidly Resorbable Gelatin-based Microspheres for Osteoarthritis-related Knee Pain. Radiology. 2026. PMID: 42301014. doi:10.1148/radiol.253312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。